search
Back to results

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

Primary Purpose

Primary Sjögren's Syndrome

Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
VAY736 lower dose
VAY736 higher dose
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Sjögren's Syndrome focused on measuring Primary Sjögren's syndrome, Sicca syndrome, Salivary glands, Positron Emission Tomography, B cell depletion

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Part 1 and 3:

Inclusion Criteria:

  • Fullfilled consensus criteria for primary Sjögren's syndrome
  • Patients must have elevated serum levels for some Sögren Syndorme specific parameters such as antinuclear antibodies (ANA), rheumatoid factor (RF) etc.

Exclusion Criteria:

  • Patients that are suffering from Secondary Sjögren's syndrome.
  • Patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc.

Part 2

Inclusion criteria:

- healthy male and female people 18-75 years of age

Exclusion criteria:

  • Use of other investigational drugs at the time of enrollment
  • Exposure to a sizeable degree of radiation (≥ 5 mSv) in an investigational research study in the past year prior to this study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    VAY736 lower dose

    VA736 higher dose

    Arm Description

    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)

    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)

    Outcomes

    Primary Outcome Measures

    Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging
    Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with [Zr- 89]rituximab
    Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab
    Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with [Zr-89]-rituximab (e.g. 3 days after injection)
    Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging
    Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with [Zr-89]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment

    Secondary Outcome Measures

    Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments
    AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)
    To assess the pharmacokinetiks of VAY736 in pSS patients
    Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose
    Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS
    Multiple s.c. dose VAY736 PD parameter - depletion of B cells
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Assess salivary glands size and echostructure by ultrasound
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Assess lacrimal gland function by Schirmer's test
    To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity
    Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).
    To evaluate the effect of on self-reported outcomes in pSS patients
    Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)
    To evaluate the change in the physician global assessment of patients's overall disease activity
    Physician's visual anaglog scale (VAS)
    To evaluate the change in the patients global assessment of their disease activity
    Patient's visual analogue scale (VAS)
    To assess the immunogenicity of VAY736
    Anti-VAY736 antibodies
    To assess the immunogenicity of a micodose of rituximab
    Anti-rituximab antibodies
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Multiple s.c. dose VAY736 PK parameter - Cmax
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Multiple s.c. dose VAY736 PK parameter - tmax
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Multiple s.c. dose VAY736 PK parameter - half live (t1/2)

    Full Information

    First Posted
    July 8, 2015
    Last Updated
    April 19, 2017
    Sponsor
    Novartis Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02495129
    Brief Title
    Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
    Official Title
    A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    December 2015 (undefined)
    Primary Completion Date
    September 2017 (Anticipated)
    Study Completion Date
    September 2017 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Novartis Pharmaceuticals

    4. Oversight

    5. Study Description

    Brief Summary
    This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method is a valid method to assess B cells in salivary glands of pSS patients. In Part 1 and Part 2 no IMP will be applied to the subjects. In Part 3, pSS patients (n=12) will receive the IMP, VAY736. Posted information will be focused on Part 3. The overarching purpose of this study is to test a new drug (VAY736) for the treatment of pSS. In pSS, the salivary glands (the glands that produce saliva) and other organs are affected by inflammation. A certain type of white blood cells called B cells prominently infiltrate the salivary glands in pSS, whereas they are not present in healthy salivary glands. Scientific evidence suggests that B cells may be involved in the disease process in pSS and that eliminating B cells may benefit patients with pSS. This study will test a new imaging method and a new treatment for pSS. Both the imaging method and the treatment are specific for B cells.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Primary Sjögren's Syndrome
    Keywords
    Primary Sjögren's syndrome, Sicca syndrome, Salivary glands, Positron Emission Tomography, B cell depletion

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    VAY736 lower dose
    Arm Type
    Experimental
    Arm Description
    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
    Arm Title
    VA736 higher dose
    Arm Type
    Experimental
    Arm Description
    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
    Intervention Type
    Drug
    Intervention Name(s)
    VAY736 lower dose
    Intervention Description
    Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
    Intervention Type
    Drug
    Intervention Name(s)
    VAY736 higher dose
    Intervention Description
    Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
    Primary Outcome Measure Information:
    Title
    Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging
    Description
    Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with [Zr- 89]rituximab
    Time Frame
    Part 1: 4 weeks
    Title
    Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab
    Description
    Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with [Zr-89]-rituximab (e.g. 3 days after injection)
    Time Frame
    Part 2: 4 weeks
    Title
    Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging
    Description
    Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with [Zr-89]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment
    Time Frame
    Part 3: 12 weeks
    Secondary Outcome Measure Information:
    Title
    Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments
    Description
    AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)
    Time Frame
    12 weeks
    Title
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Description
    Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)
    Time Frame
    12 weeks
    Title
    To assess the pharmacokinetiks of VAY736 in pSS patients
    Description
    Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose
    Time Frame
    12 weeks
    Title
    Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS
    Description
    Multiple s.c. dose VAY736 PD parameter - depletion of B cells
    Time Frame
    12 weeks
    Title
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Description
    Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements
    Time Frame
    12 weeks
    Title
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Description
    Assess salivary glands size and echostructure by ultrasound
    Time Frame
    12 weeks
    Title
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Description
    Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)
    Time Frame
    12 weeks
    Title
    Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
    Description
    Assess lacrimal gland function by Schirmer's test
    Time Frame
    12 weeks
    Title
    To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity
    Description
    Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).
    Time Frame
    12 weeks
    Title
    To evaluate the effect of on self-reported outcomes in pSS patients
    Description
    Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)
    Time Frame
    12 weeks
    Title
    To evaluate the change in the physician global assessment of patients's overall disease activity
    Description
    Physician's visual anaglog scale (VAS)
    Time Frame
    12 weeks
    Title
    To evaluate the change in the patients global assessment of their disease activity
    Description
    Patient's visual analogue scale (VAS)
    Time Frame
    12 weeks
    Title
    To assess the immunogenicity of VAY736
    Description
    Anti-VAY736 antibodies
    Time Frame
    12 weeks
    Title
    To assess the immunogenicity of a micodose of rituximab
    Description
    Anti-rituximab antibodies
    Time Frame
    25 weeks
    Title
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Description
    Multiple s.c. dose VAY736 PK parameter - Cmax
    Time Frame
    12 weeks
    Title
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Description
    Multiple s.c. dose VAY736 PK parameter - tmax
    Time Frame
    12 weeks
    Title
    To asses the pharmacokinetiks of VAY736 in pSS patients
    Description
    Multiple s.c. dose VAY736 PK parameter - half live (t1/2)
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Part 1 and 3: Inclusion Criteria: Fullfilled consensus criteria for primary Sjögren's syndrome Patients must have elevated serum levels for some Sögren Syndorme specific parameters such as antinuclear antibodies (ANA), rheumatoid factor (RF) etc. Exclusion Criteria: Patients that are suffering from Secondary Sjögren's syndrome. Patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc. Part 2 Inclusion criteria: - healthy male and female people 18-75 years of age Exclusion criteria: Use of other investigational drugs at the time of enrollment Exposure to a sizeable degree of radiation (≥ 5 mSv) in an investigational research study in the past year prior to this study

    12. IPD Sharing Statement

    Learn more about this trial

    Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

    We'll reach out to this number within 24 hrs